Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
HTG Molecular Diagnostics Inc is a diagnostics & research business based in the US. HTG Molecular Diagnostics shares (HTGM) are listed on the NASDAQ and all prices are listed in US Dollars. HTG Molecular Diagnostics employs 83 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.66|
|52-week range||$3.50 - $7.95|
|50-day moving average||$5.98|
|200-day moving average||$5.29|
|Wall St. target price||$9.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.04|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.05%|
|1 month (2021-09-24)||-5.82%|
|3 months (2021-07-23)||5.40%|
|6 months (2021-04-23)||31.32%|
|1 year (2020-10-23)||1,741.85%|
|2 years (2019-10-24)||569.51%|
|3 years (2018-10-24)||58.99%|
|5 years (2016-10-24)||133.88%|
|Revenue TTM||$7.9 million|
|Gross profit TTM||$-1,522,575|
|Return on assets TTM||-28.84%|
|Return on equity TTM||-92.47%|
|Market capitalisation||$42.4 million|
TTM: trailing 12 months
There are currently 125,947 HTG Molecular Diagnostics shares held short by investors – that's known as HTG Molecular Diagnostics's "short interest". This figure is 27% down from 172,523 last month.
There are a few different ways that this level of interest in shorting HTG Molecular Diagnostics shares can be evaluated.
HTG Molecular Diagnostics's "short interest ratio" (SIR) is the quantity of HTG Molecular Diagnostics shares currently shorted divided by the average quantity of HTG Molecular Diagnostics shares traded daily (recently around 35180.726256983). HTG Molecular Diagnostics's SIR currently stands at 3.58. In other words for every 100,000 HTG Molecular Diagnostics shares traded daily on the market, roughly 3580 shares are currently held short.
However HTG Molecular Diagnostics's short interest can also be evaluated against the total number of HTG Molecular Diagnostics shares, or, against the total number of tradable HTG Molecular Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HTG Molecular Diagnostics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 HTG Molecular Diagnostics shares in existence, roughly 20 shares are currently held short) or 0.0236% of the tradable shares (for every 100,000 tradable HTG Molecular Diagnostics shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against HTG Molecular Diagnostics.
Find out more about how you can short HTG Molecular Diagnostics stock.
We're not expecting HTG Molecular Diagnostics to pay a dividend over the next 12 months.
HTG Molecular Diagnostics's shares were split on a 1:15 basis on 22 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your HTG Molecular Diagnostics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for HTG Molecular Diagnostics shares which in turn could have impacted HTG Molecular Diagnostics's share price.
Over the last 12 months, HTG Molecular Diagnostics's shares have ranged in value from as little as $3.5 up to $7.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HTG Molecular Diagnostics's is 1.4804. This would suggest that HTG Molecular Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.